Have a feature idea you'd love to see implemented?
Let us know!
CNTA Centessa Pharmaceuticals plc
Price (delayed)
$18.19
Market cap
$2.4B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.52
Enterprise value
$2.09B
Highlights
Centessa Pharmaceuticals's quick ratio has surged by 144% YoY and by 78% QoQ
CNTA's equity has soared by 92% YoY and by 74% QoQ
The net income has contracted by 2.5% from the previous quarter and by 2.4% YoY
Key stats
What are the main financial stats of CNTA
Market
Valuations
Earnings
Shares outstanding
131.85M
Market cap
$2.4B
Enterprise value
$2.09B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.13
Price to sales (P/S)
308.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
304.59
Revenue
$6.85M
EBIT
-$148.15M
EBITDA
-$147.19M
Free cash flow
-$130.37M
Per share
Balance sheet
Liquidity
EPS
-$1.52
Free cash flow per share
-$1.12
Book value per share
$4.4
Revenue per share
$0.06
TBVPS
$5.24
Total assets
$609.72M
Total liabilities
$110.58M
Debt
$84.14M
Equity
$499.14M
Working capital
$541.96M
Debt to equity
0.17
Current ratio
21.52
Quick ratio
19.63
Net debt/EBITDA
2.11
Margins
Efficiency
Dividend
EBITDA margin
-2,147.8%
Gross margin
100%
Net margin
-2,353.2%
Operating margin
-2,338.4%
Return on assets
-38%
Return on equity
-52.1%
Return on invested capital
-51.6%
Return on capital employed
-25.4%
Return on sales
-2,161.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CNTA stock price
How has the Centessa Pharmaceuticals stock price performed over time
Intraday
8.66%
1 week
3.94%
1 month
15.2%
1 year
177.71%
YTD
128.52%
QTD
13.76%
Financial performance
How have Centessa Pharmaceuticals's revenue and profit performed over time
Revenue
$6.85M
Gross profit
$6.85M
Operating income
-$160.25M
Net income
-$161.27M
Gross margin
100%
Net margin
-2,353.2%
The operating income has grown by 12% YoY
The net income has contracted by 2.5% from the previous quarter and by 2.4% YoY
The net margin has declined by 2.5% since the previous quarter
Growth
What is Centessa Pharmaceuticals's growth rate over time
Valuation
What is Centessa Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.13
P/S
308.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
304.59
The company's EPS rose by 7% YoY
CNTA's equity has soared by 92% YoY and by 74% QoQ
CNTA's price to book (P/B) is 6% higher than its last 4 quarters average of 3.9
CNTA's P/S is 78% above its last 4 quarters average of 173.0
Efficiency
How efficient is Centessa Pharmaceuticals business performance
Centessa Pharmaceuticals's return on invested capital has increased by 39% YoY
The company's return on equity rose by 17% QoQ and by 3.5% YoY
Centessa Pharmaceuticals's return on assets has increased by 12% QoQ and by 2.3% YoY
Dividends
What is CNTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CNTA.
Financial health
How did Centessa Pharmaceuticals financials performed over time
Centessa Pharmaceuticals's quick ratio has surged by 144% YoY and by 78% QoQ
CNTA's current ratio has surged by 126% year-on-year and by 62% since the previous quarter
The debt is 83% smaller than the equity
CNTA's equity has soared by 92% YoY and by 74% QoQ
Centessa Pharmaceuticals's debt to equity has decreased by 47% YoY and by 43% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.